CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 100 enrolled
Drug / intervention
Guadecitabinedrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02131597
NCT02131597Phase 2Completed
CompareCT.gov

Phase 2 Study of SGI-110 in Patients With Higher Risk MDS

M.D. Anderson Cancer Center·interventional·Posted May 6, 2014·Updated Jul 17, 2025

In Brief

A Phase 2 clinical trial evaluating Guadecitabine for High Risk Myelodysplastic Syndrome. Completed, enrolled 100 participants across 1 site.

Detailed Summary

This phase II trial studies how well guadecitabine works in treating patients with myelodysplastic syndromes that are at higher risk for becoming acute myeloid leukemia. Guadecitabine may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHigh Risk Myelodysplastic Syndrome
CountriesUnited States
CollaboratorsNational Cancer Institute (NCI)

Timeline

Phase 2CompletedFinished
201520162017201820192020202120222023202420252026
First PostedMay 6, 2014
Enrollment StartNov 10, 2014
Primary CompletionJul 25, 2024
TodayJul 2, 2026
Enrollment to primary: 9.7 yearsPosted 12.2 years ago

Interventions

Guadecitabinedrug

Given SC